Daily Vitamin D Supplements: What the Evidence Says

Daily vitamin D tablets reliably prevent rickets and osteomalacia and correct deficiency, but large randomised trials show little or no benefit for most other outcomes in healthy adults. The strongest case for supplementing is for people who are deficient, infants, pregnant women, and adults aged 75 and over.

What vitamin D is and what it does

Vitamin D is a fat-soluble vitamin that occurs naturally in very few foods, is added to a few others, is sold as a supplement, and is made in the skin when ultraviolet light from the sun strikes it (NIH Office of Dietary Supplements). Vitamin D from sun, food or tablets is biologically inert until the body activates it in two steps, first in the liver and then mainly in the kidney. The liver product, 25-hydroxyvitamin D, is the form measured in a blood test.

Its best-established job is to help the gut absorb calcium and to keep blood calcium and phosphate high enough for bones to mineralise normally. Without enough of it, bones can become thin, brittle or misshapen (NIH, via LOINC).

Supplements come in two forms, D2 (ergocalciferol) and D3 (cholecalciferol), which differ chemically only in their side chains. Fat in the gut improves absorption, although some vitamin D is absorbed without it, so taking a tablet with a meal is sensible (NIH Office of Dietary Supplements).

One complication runs through the whole debate: researchers have not definitively agreed which blood levels count as deficient, adequate for bones, or adequate for overall health. Healthy Bones Australia suggests at least 50 nmol/L at the end of winter (Healthy Bones Australia), while a global consensus on rickets defines deficiency as below 30 nmol/L (global consensus on nutritional rickets). Many of the conflicting trial results below make more sense once you ask how low participants’ levels were when they started.

Who is low in vitamin D

In Australia, Healthy Bones Australia reports that over 30% of adults have a mild, moderate or severe deficiency (Healthy Bones Australia). The Australian Bureau of Statistics estimate quoted by Jean Hailes is lower, at just under one in four adults (Jean Hailes). The gap most likely reflects different cut-offs for “deficient”, which is the definitional problem noted above.

Sun is the main source for Australians, but how much vitamin D it delivers depends on season, location, skin type and how much skin is exposed. Because sun protection is advised whenever the UV Index is 3 or above, the sun alone does not guarantee adequate levels (Healthy Bones Australia). Food does not fill the gap either. A Curtin University analysis found that most Australians eat less than half of the international recommended intake of 10 µg a day (Curtin University).

The same Curtin work names the groups at higher risk: Aboriginal and Torres Strait Islander people in remote areas, people born outside Australia or the main English-speaking countries, people living in the southern states, and people who are obese or physically inactive. Older people in institutional care are another high-risk group. An Australian and New Zealand position statement reported that up to 80% of women and 70% of men in hostels or nursing homes in Victoria, New South Wales and Western Australia were frankly deficient, though that paper dates from 2005 and the figures may have changed (Medical Journal of Australia).

Bone health: the clearest benefit

The most solid benefit of vitamin D is the prevention of rickets in children and osteomalacia in adults, both diseases of poorly mineralised bone. Together with calcium, it also helps protect older adults from osteoporosis (NIH, via LOINC).

A global consensus on nutritional rickets concluded that these conditions are preventable public health problems. It found that 400 IU a day is enough to prevent rickets, and recommended that all infants receive 400 IU daily until 12 months of age, with food fortification used to lift population intakes to the same level (global consensus on nutritional rickets, ESPE abstract). A separate review adds that the global incidence of rickets and osteomalacia is rising, partly because prevention policies are not well implemented (MDPI review).

In Australia, Healthy Bones Australia notes that low vitamin D can reduce the calcium absorbed from food and, in severe cases, cause rickets (Healthy Bones Australia). Severe deficiency is rare in Australia and New Zealand, while mild deficiency is more common and is associated with higher parathyroid hormone and faster bone turnover (MJA position statement).

The key distinction is between treating deficiency and supplementing people who are already replete. For deficient people the case is strong and long-standing. For people with adequate levels, the evidence for extra bone benefit is much weaker, as the next section shows.

Falls and fractures: where the evidence conflicts

Vitamin D supplements have long been recommended to older people to prevent falls and fractures, but the trial evidence has shifted. Reviews published at different times, using different trials, reach different conclusions.

The most consistent pattern is about dose schedule. Modest daily doses, in the range of 700 to 1,000 IU, are linked to fewer falls in several analyses, while large infrequent doses show no benefit and may do harm. The Endocrine Society guideline reflects this, suggesting daily administration rather than intermittent high doses for people over 50 who need vitamin D (Endocrine Society guideline, PubMed).

The 81-trial analysis is the most sceptical. Its authors said guidelines that recommend vitamin D for bone health should change to reflect the evidence, and they noted that fall data were collected differently across trials, which may affect results (CME summary). Taken together, the larger and more recent analyses do not support routine supplements to protect bones in generally healthy older adults, and whether people who start with low levels gain more is not settled by these trials.

Immunity and respiratory infections

The idea that vitamin D protects against colds and chest infections has been tested in dozens of trials, and the answer has moved from a modest benefit to an uncertain one as more data arrived.

An individual-participant analysis in 2019 found that supplements reduced the odds of an acute respiratory infection (adjusted odds ratio 0.88, 95% CI 0.81 to 0.96). The protection was seen in people taking daily or weekly doses (0.81), but not in those who received one or more large bolus doses (0.97), and supplementation did not increase serious adverse events (Health Technology Assessment, 2019). A 2021 meta-analysis of aggregate trial data pooled 37 trials and also found a small protective effect (odds ratio 0.92, 95% CI 0.86 to 0.99) (2021 meta-analysis).

The most recent update, published in 2025, found a similar overall estimate, but its confidence interval now includes 1.00, which means the protective effect is no longer statistically significant (Lancet Diabetes & Endocrinology, 2025). Two other meta-analyses, one of prevention and one of treatment of established infections, concluded that vitamin D has no clinically important effect in the higher-quality trials (prevention meta-analysis; treatment meta-analysis). A 2024 dose-response analysis suggested that any slight preventive effect is most likely with daily doses of roughly 400 to 1,200 IU (Nutrition Journal).

The fair reading is that daily vitamin D may trim the risk of respiratory infections slightly, but the effect is small and the latest pooled estimate does not rule out no effect at all.

Cancer and heart disease: the VITAL trial

The best test of whether vitamin D prevents cancer or heart disease is VITAL, a randomised, placebo-controlled trial of 25,871 US men aged 50 and over and women aged 55 and over, including 5,106 African Americans. Participants took 2,000 IU of vitamin D3 a day, 1 g of marine omega-3, both, or placebo, for a median of 5.3 years (Principal results of VITAL).

Vitamin D did not significantly reduce major cardiovascular events (hazard ratio 0.97, 95% CI 0.85 to 1.12) or deaths from any cause (hazard ratio 0.99, 95% CI 0.87 to 1.12) (PubMed abstract). In raw numbers, 396 people in the vitamin D group and 409 on placebo had a major cardiovascular event, and invasive cancer was diagnosed in 793 and 824 people respectively (American College of Cardiology). Neither difference was statistically significant.

There was one tantalising signal. Deaths from cancer appeared lower in the vitamin D group, and updated meta-analyses including VITAL show a significant reduction in cancer mortality but not in cancer incidence or cardiovascular endpoints (PubMed abstract). The trial investigators told participants that this result needs to be confirmed (VITAL study findings). An independent commentator at the American Heart Association presentation, Jane Armitage, called VITAL a robust test of the null hypothesis and warned that secondary results risk being spurious (PACE-CME).

The practical conclusion is that taking vitamin D does not lower the chance of developing cancer or heart disease in generally healthy older adults. The possible effect on cancer deaths is a lead for further research, not a reason to start taking tablets.

Autoimmune disease and mood

Autoimmune disease. The most encouraging result from VITAL came from a later analysis of autoimmune disease, published in the BMJ in 2022. Over five years, 123 people taking vitamin D developed a confirmed autoimmune disease, compared with 155 on placebo, a 22% reduction (hazard ratio 0.78, 95% CI 0.61 to 0.99). The conditions counted included rheumatoid arthritis, polymyalgia rheumatica, autoimmune thyroid disease and psoriasis (Harvard Gazette; Duke RheumMadness). A conference abstract on 7.5 years of follow-up reported a similar 21% reduction, with a stronger effect in people of normal weight (Annals of the Rheumatic Diseases abstract).

There are two reasons for caution. The finding was a secondary analysis, and the absolute numbers are small: a Duke rheumatology review estimated that about 500 people would need to take vitamin D for five years to prevent one case of autoimmune disease (Duke RheumMadness). The result is promising, but it is not yet a firm basis for recommending supplements to everyone.

Depression. Observational studies link low vitamin D with depression, which made the hypothesis attractive. The randomised evidence does not support it. VITAL-DEP followed 18,353 adults aged 50 and over for a median of 5.3 years and found no difference in the risk of depression, or in mood scores, between vitamin D3 (2,000 IU a day) and placebo (JAMA, 2020). Its authors noted that of 13 randomised trials of vitamin D3 and depression or mood in middle-aged and older adults, all but one had null findings (MDedge). One caveat from commentators is that average vitamin D levels in the trial were normal, so it cannot say whether supplements help people who are deficient (McMaster Optimal Aging).

The NIH consumer fact sheet takes the same line: trials show that vitamin D supplements do not prevent or ease depression, do not stop most people with prediabetes from developing diabetes, and do not help with weight loss (NIH Office of Dietary Supplements).

Pregnancy and childhood

Infants and children. Infants are the group with the clearest case for a daily tablet or drops. Breast milk contains little vitamin D, which is why exclusively breastfed infants are at particular risk (MDPI review), and the global rickets consensus recommends 400 IU a day for all infants until 12 months of age (ESPE abstract). The 2024 Endocrine Society guideline also suggests empiric vitamin D for children and adolescents aged 1 to 18 (HealthDay).

Pregnancy. Here the evidence is genuinely mixed. The Endocrine Society suggests supplementation in pregnancy, with the aim of lowering the risk of pre-eclampsia, preterm birth and neonatal death (HippoEd summary). A 2019 Cochrane review had found that vitamin D alone may reduce the risk of pre-eclampsia (Medical Dialogues summary). The 2024 Cochrane update, which removed 20 earlier studies over trustworthiness concerns, rated the evidence as very uncertain for pre-eclampsia, gestational diabetes and preterm birth. It found low-certainty evidence of a possible reduction in severe postpartum haemorrhage and low birthweight, and concluded that the evidence does not strongly support routine supplementation (Links Medicus summary of the Cochrane review).

Other recent analyses disagree with each other. A 2024 meta-analysis of 38 outcomes reported no significant effect of antenatal vitamin D on pre-eclampsia (Nutrition Reviews), while a separate meta-analysis of trials through August 2024 reported a significant reduction in pre-eclampsia and preterm labour (PMC). On safety, a Cochrane review of dosing regimens covering 30 trials and 7,289 women found that doses above the current upper limit did not appear to increase the risks assessed, although the safety measures reported were inconsistent (PubMed).

In short, a standard vitamin D tablet in pregnancy looks safe and is endorsed by the Endocrine Society, but the claimed benefits for pregnancy outcomes remain unproven. Anyone who is pregnant should discuss dose with their midwife or doctor.

Dose and safety

Most adults need only about 600 IU (15 µg) a day, and the Mayo Clinic advises not exceeding 4,000 IU a day unless a health professional says otherwise (Mayo Clinic). Australian guidance from Healthy Bones Australia is somewhat higher for people who do not get enough sun, and is framed as a general guide only (Healthy Bones Australia).

Vitamin D toxicity is rare and is usually caused by taking large doses of supplements, not by food or sun. Its main effect is a build-up of calcium in the blood (hypercalcaemia), which can cause nausea, vomiting, weakness and frequent urination, and treatment starts with stopping the supplement (Mayo Clinic). The NIH notes that high blood levels are almost always caused by excessive supplement intake (NIH Office of Dietary Supplements).

The 4,000 IU ceiling is not a guarantee of safety. A 2023 meta-analysis of trials lasting at least six months found that 3,200 to 4,000 IU a day appears to raise the risk of hypercalcaemia and some other adverse events in a small proportion of people (European Journal of Nutrition). In one three-year trial of healthy, vitamin D-replete adults, hypercalcaemia occurred in 0%, 3% and 9% of those taking 400, 4,000 and 10,000 IU a day (review in PMC).

Two further points. First, the Endocrine Society advises against routine blood testing of vitamin D in healthy people, and its guideline does not cover people with kidney or liver disease, malabsorption or certain cancers, who need individual advice (University of Minnesota College of Pharmacy). Second, more is not better: the clearest benefits shown in trials are from correcting low levels, and the higher-dose trials above show a small increase in hypercalcaemia.

Practical takeaways

Who benefits most from a daily tablet depends on starting level and life stage. The Endocrine Society’s 2024 guideline, written for generally healthy people, is the most useful single guide.

If you do take a supplement:

• Choose D3 or D2 and take it daily, with a meal that contains some fat, because fat improves absorption (NIH Office of Dietary Supplements).

• Count vitamin D from multivitamins and fortified foods towards the 4,000 IU a day ceiling (Mayo Clinic).

• Ask your doctor about testing only if you have risk factors, since healthy people are not advised to have routine tests (University of Minnesota College of Pharmacy).

This article summarises published research and is not personal medical advice. A GP or pharmacist can tailor a dose to your health, medicines and sun exposure.

Sources

Figures in this article come from the abstracts and excerpts of the pages below, retrieved on 12 October 2026. Check the original paper before relying on a specific number.

Guidelines and fact sheets

• NIH Office of Dietary Supplements, Vitamin D fact sheet for health professionals

• NIH Office of Dietary Supplements, Vitamin D fact sheet for consumers

• Endocrine Society guideline, Vitamin D for the Prevention of Disease (2024), PubMed

• Pharmacist.com summary of the Endocrine Society guideline

• University of Minnesota College of Pharmacy, comparing the 2011 and 2024 guidelines

• Global consensus recommendations on nutritional rickets and ESPE abstract

• Healthy Bones Australia, Vitamin D and bone health

• Mayo Clinic, What is vitamin D toxicity?

Trials and meta-analyses

• VITAL principal results and updated meta-analyses, PMC and PubMed abstract

• VITAL study findings, American College of Cardiology report and PACE-CME report

• VITAL autoimmune disease analysis, Harvard Gazette, Duke RheumMadness review and follow-up abstract

• VITAL-DEP depression trial, JAMA 2020, MDedge and McMaster Optimal Aging

• Respiratory infections: 2019 individual-participant analysis, 2021 meta-analysis, 2025 update, prevention meta-analysis, treatment meta-analysis, dose-response analysis

• Falls and fractures: 81-trial meta-analysis summary, AAFP, Relias summary, network meta-analysis, high-dose meta-analysis

• Pregnancy: Cochrane 2024 summary, Cochrane 2019 summary, Cochrane regimens review, Nutrition Reviews meta-analysis, pre-eclampsia meta-analysis

• Safety: 3,200 to 4,000 IU meta-analysis and upper limit review

Australian context

• Jean Hailes, Curtin University and Medical Journal of Australia position statement (2005)

• Other pages cited above: MDPI rickets review, HealthDay, HippoEd, NIH via LOINC

Primary guidance: NIH Vitamin D Fact Sheet · Endocrine Society 2024 Guideline